Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SCOTT E JORDAN

Allopathic & Osteopathic Physicians Obstetrics & Gynecology

NPI
1487916649
CMS profile
775934
Location
FORT LAUDERDALE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$60,549.97

63 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 2; records 51–63 of 63 matching records. This page contains 13 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SCOTT E JORDAN

NPI 1487916649 · CMS profile ID 775934

Allopathic & Osteopathic Physicians / Obstetrics & Gynecology

FORT LAUDERDALE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–63 of 63 matching records. This page contains 13 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1487916649?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SCOTT E JORDAN, NPI 1487916649, CMS profile ID 775934. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–63 of 63 matching records. This page contains 13 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1487916649?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). SCOTT E JORDAN, NPI 1487916649, CMS profile ID 775934. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–63 of 63 matching records. This page contains 13 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1487916649?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
SCOTT E JORDAN, NPI 1487916649, CMS profile ID 775934, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–63 of 63 matching records. This page contains 13 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1487916649?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

63 matching records · $60,549.97 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 63 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–63 of 63.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Medical Device Business Services, Inc. $126.0804/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991080947 CMS
Ethicon US, LLC $2.6103/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 990890811 CMS
Ethicon US, LLC $5.2103/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 990890815 CMS
Seagen Inc. $120.3603/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995670259 CMS
Aroa Biosurgery Incorporated $68.0203/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057917369 CMS
Hologic Sales and Service, LLC $149.6703/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1024848723 CMS
Seagen Inc. $121.0003/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995670287 CMS
Seagen Inc. $6.9403/14/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995670293 CMS
Seagen Inc. $3,375.0003/14/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995670301 CMS
Seagen Inc. $124.9903/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995670279 CMS
Seagen Inc. $74.9802/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 995670189 CMS
Aroa Biosurgery Incorporated $52.2501/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057917241 CMS
Heron Therapeutics, Inc. $96.8001/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1052744095 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $274.75 4
PY2020 $293.44 3
PY2021 $9,438.68 11
PY2022 $41,979.43 52
PY2023 $60,549.97 63
PY2024 $75,217.16 87
PY2025 $128,636.64 139

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,270.00 2
PY2025 Principal investigator $189,276.18 118
PY2024 Principal investigator $74,662.45 129
PY2023 Principal investigator $29,214.27 155
PY2022 Principal investigator $319,057.01 107
PY2021 Principal investigator $181,252.00 5

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

120 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,477.05 12/04/2025 Covered Recipient Teaching Hospital
BROWARD HEALTH MEDICAL CENTER
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA) No dispute reported 06/30/2026 1202406970
Principal investigator 1 Daiichi Sankyo Inc. $6,194.50 11/20/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
DS8201-772 No dispute reported 06/30/2026 1223351503
Recipient PFIZER INC. $940.00 11/05/2025 Covered Recipient Physician TISOTUMAB VEDOTIN TFTV CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228726662
Principal investigator 1 Incyte Corporation $11.76 11/03/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 1240470468
Principal investigator 1 Incyte Corporation $29.85 11/03/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 1240470474
Principal investigator 1 PFIZER INC. $1,500.00 10/15/2025 Covered Recipient Teaching Hospital
BROWARD HEALTH MEDICAL CENTER
A PROSPECTIVE LOWINTERVENTIONAL PHASE 4 SINGLE ARM STUDY OF OCULAR ASSESSMENTS IN PATIENTS TREATED WITH TIVDAK IN RECURRENT OR METASTATIC CERVICAL CANCER No dispute reported 06/30/2026 1228735260
Principal investigator 1 Daiichi Sankyo Inc. $2,174.70 10/02/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
DS8201-772 No dispute reported 06/30/2026 1223351501
Principal investigator 1 Incyte Corporation $11.76 10/01/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 1240470470
Principal investigator 1 Incyte Corporation $11.76 10/01/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 1240470472
Principal investigator 1 Karyopharm Therapeutics Inc. $219.24 09/29/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659679
Principal investigator 1 Karyopharm Therapeutics Inc. $1,000.00 09/29/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659721
Principal investigator 1 Karyopharm Therapeutics Inc. $9,240.84 09/29/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659729
Principal investigator 1 Karyopharm Therapeutics Inc. $469.04 09/29/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659825
Principal investigator 1 Daiichi Sankyo Inc. $600.00 09/18/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
DS8201-772 No dispute reported 06/30/2026 1223351491
Principal investigator 1 Daiichi Sankyo Inc. $674.70 09/16/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
DS8201-772 No dispute reported 06/30/2026 1223351493
Principal investigator 1 PFIZER INC. $2,800.00 09/16/2025 Covered Recipient Teaching Hospital
BROWARD HEALTH MEDICAL CENTER
A PROSPECTIVE LOWINTERVENTIONAL PHASE 4 SINGLE ARM STUDY OF OCULAR ASSESSMENTS IN PATIENTS TREATED WITH TIVDAK IN RECURRENT OR METASTATIC CERVICAL CANCER No dispute reported 06/30/2026 1228748665
Principal investigator 1 Daiichi Sankyo Inc. $197.20 09/10/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
DS8201-772 No dispute reported 06/30/2026 1223351495
Principal investigator 1 ABBVIE INC. $600.00 09/03/2025 Covered Recipient Teaching Hospital
BROWARD HEALTH MEDICAL CENTER
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA) No dispute reported 06/30/2026 1202406966
Principal investigator 1 Incyte Corporation $11.76 09/02/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 1240470456
Principal investigator 1 Incyte Corporation $29.85 09/02/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 1240470460
Principal investigator 1 Incyte Corporation $11.76 09/02/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 1240470462
Principal investigator 1 Incyte Corporation $11.76 09/02/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 1240470464
Principal investigator 1 Karyopharm Therapeutics Inc. $119.70 08/27/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659675
Principal investigator 1 Karyopharm Therapeutics Inc. $1,363.32 08/27/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659681
Principal investigator 1 Karyopharm Therapeutics Inc. $1,449.00 08/27/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659687
Principal investigator 1 Karyopharm Therapeutics Inc. $1,645.32 08/27/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659695
Principal investigator 1 Karyopharm Therapeutics Inc. $246.96 08/27/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659699
Principal investigator 1 Karyopharm Therapeutics Inc. $1,155.42 08/27/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659709
Principal investigator 1 Karyopharm Therapeutics Inc. $1,645.32 08/27/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659731
Principal investigator 1 Karyopharm Therapeutics Inc. $1,181.88 08/27/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659735
Principal investigator 1 Karyopharm Therapeutics Inc. $1,363.32 08/27/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659745
Principal investigator 1 Karyopharm Therapeutics Inc. $1,363.32 08/27/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659773
Principal investigator 1 Karyopharm Therapeutics Inc. $2,056.32 08/27/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659777
Principal investigator 1 Karyopharm Therapeutics Inc. $119.70 08/27/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659785
Principal investigator 1 Karyopharm Therapeutics Inc. $2,056.32 08/27/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659805
Principal investigator 1 Karyopharm Therapeutics Inc. $1,277.64 08/27/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659809
Principal investigator 1 Karyopharm Therapeutics Inc. $246.96 08/27/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659811
Principal investigator 1 Karyopharm Therapeutics Inc. $1,363.32 08/27/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659823
Principal investigator 1 Karyopharm Therapeutics Inc. $1,645.32 08/27/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659833
Principal investigator 1 Karyopharm Therapeutics Inc. $1,363.32 08/27/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659835
Principal investigator 1 Karyopharm Therapeutics Inc. $2,056.32 08/27/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659837
Principal investigator 1 Karyopharm Therapeutics Inc. $7,190.82 08/18/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659761
Principal investigator 1 Karyopharm Therapeutics Inc. $2,985.62 08/18/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659775
Principal investigator 1 Karyopharm Therapeutics Inc. $1,000.00 08/18/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659787
Principal investigator 1 PFIZER INC. $250.00 08/15/2025 Covered Recipient Teaching Hospital
BROWARD HEALTH MEDICAL CENTER
A RANDOMIZED OPENLABEL PHASE 3 TRIAL OF TISOTUMAB VEDOTIN VS INVESTIGATORS CHOICE CHEMOTHERAPY IN SECOND OR THIRDLINE RECURRENT OR METASTATIC CERVICAL CANCER No dispute reported 06/30/2026 1228712442
Principal investigator 1 Karyopharm Therapeutics Inc. $108.36 07/29/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659689
Principal investigator 1 Karyopharm Therapeutics Inc. $2,953.64 07/29/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659739
Principal investigator 1 Karyopharm Therapeutics Inc. $1,000.00 07/29/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659741
Principal investigator 1 Karyopharm Therapeutics Inc. $3,213.84 07/29/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659795
Principal investigator 1 ABBVIE INC. $12,657.48 07/22/2025 Covered Recipient Teaching Hospital
BROWARD HEALTH MEDICAL CENTER
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA) No dispute reported 06/30/2026 1202406962
Principal investigator 1 Daiichi Sankyo Inc. $600.00 07/10/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
DS8201-772 No dispute reported 06/30/2026 1223351489
Principal investigator 1 Daiichi Sankyo Inc. $2,800.00 07/10/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
DS8201-772 No dispute reported 06/30/2026 1223351497
Principal investigator 1 Daiichi Sankyo Inc. $600.00 07/10/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
DS8201-772 No dispute reported 06/30/2026 1223351499
Principal investigator 1 Incyte Corporation $29.85 07/01/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 1240470458
Principal investigator 1 Incyte Corporation $35.04 07/01/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 1240470466
Principal investigator 1 Karyopharm Therapeutics Inc. $1,363.32 05/15/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659707
Principal investigator 1 Karyopharm Therapeutics Inc. $1,363.32 05/15/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659737
Principal investigator 1 Karyopharm Therapeutics Inc. $1,363.32 05/15/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659743
Principal investigator 1 Karyopharm Therapeutics Inc. $3,213.84 05/15/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659757
Principal investigator 1 Karyopharm Therapeutics Inc. $1,534.68 05/15/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659779
Principal investigator 1 Karyopharm Therapeutics Inc. $1,000.00 05/15/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659799
Principal investigator 1 Karyopharm Therapeutics Inc. $7,190.82 05/15/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659817
Principal investigator 1 Karyopharm Therapeutics Inc. $1,381.44 05/15/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659839
Recipient PFIZER INC. $330.00 05/05/2025 Covered Recipient Physician TISOTUMAB VEDOTIN TFTV CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228751361
Principal investigator 1 Incyte Corporation $11.76 05/02/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 1240470446
Principal investigator 1 Incyte Corporation $11.76 05/02/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 1240470448
Principal investigator 1 Incyte Corporation $11.76 05/02/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 1240470450
Principal investigator 1 ABBVIE INC. $5,160.00 04/14/2025 Covered Recipient Teaching Hospital
BROWARD HEALTH MEDICAL CENTER
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA) No dispute reported 06/30/2026 1202406954
Principal investigator 1 ABBVIE INC. $132.86 04/14/2025 Covered Recipient Teaching Hospital
BROWARD HEALTH MEDICAL CENTER
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA) No dispute reported 06/30/2026 1202406959
Principal investigator 1 Incyte Corporation $11.76 04/02/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 1240470444
Principal investigator 1 Incyte Corporation $11.76 04/02/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 1240470452
Principal investigator 1 Incyte Corporation $11.76 04/02/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 1240470454
Principal investigator 1 Incyte Corporation $59.70 03/03/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (POD1UM-204) No dispute reported 06/30/2026 1240470442
Principal investigator 1 Karyopharm Therapeutics Inc. $1,363.32 03/03/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659725
Principal investigator 1 Karyopharm Therapeutics Inc. $1,363.32 03/03/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659827
Principal investigator 1 Karyopharm Therapeutics Inc. $1,395.79 02/26/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659685
Principal investigator 1 Karyopharm Therapeutics Inc. $6,802.74 02/26/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659719
Principal investigator 1 Karyopharm Therapeutics Inc. $1,000.00 02/26/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659723
Principal investigator 1 Karyopharm Therapeutics Inc. $6,802.74 02/26/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659765
Principal investigator 1 Karyopharm Therapeutics Inc. $1,397.43 02/26/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659767
Principal investigator 1 Karyopharm Therapeutics Inc. $6,856.92 02/26/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659815
Principal investigator 1 PFIZER INC. $750.00 02/10/2025 Covered Recipient Teaching Hospital
BROWARD HEALTH MEDICAL CENTER
A RANDOMIZED OPENLABEL PHASE 3 TRIAL OF TISOTUMAB VEDOTIN VS INVESTIGATORS CHOICE CHEMOTHERAPY IN SECOND OR THIRDLINE RECURRENT OR METASTATIC CERVICAL CANCER No dispute reported 06/30/2026 1228793796
Principal investigator 1 ABBVIE INC. $600.00 02/06/2025 Covered Recipient Teaching Hospital
BROWARD HEALTH MEDICAL CENTER
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA) No dispute reported 06/30/2026 1202406950
Principal investigator 1 Karyopharm Therapeutics Inc. $630.00 01/27/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659693
Principal investigator 1 Karyopharm Therapeutics Inc. $750.00 01/27/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659711
Principal investigator 1 Karyopharm Therapeutics Inc. $7,190.82 01/27/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659713
Principal investigator 1 Karyopharm Therapeutics Inc. $54.10 01/27/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659715
Principal investigator 1 Karyopharm Therapeutics Inc. $630.00 01/27/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659717
Principal investigator 1 Karyopharm Therapeutics Inc. $7,190.82 01/27/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659763
Principal investigator 1 Karyopharm Therapeutics Inc. $630.00 01/27/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659771
Principal investigator 1 Karyopharm Therapeutics Inc. $600.00 01/27/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659791
Principal investigator 1 Karyopharm Therapeutics Inc. $54.18 01/27/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659797
Principal investigator 1 Karyopharm Therapeutics Inc. $1,393.66 01/27/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659819
Principal investigator 1 Karyopharm Therapeutics Inc. $1,277.64 01/23/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659677
Principal investigator 1 Karyopharm Therapeutics Inc. $246.96 01/23/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659683
Principal investigator 1 Karyopharm Therapeutics Inc. $1,181.88 01/23/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659691
Principal investigator 1 Karyopharm Therapeutics Inc. $1,363.32 01/23/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659697
Principal investigator 1 Karyopharm Therapeutics Inc. $1,363.32 01/23/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659701
Principal investigator 1 Karyopharm Therapeutics Inc. $246.96 01/23/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659703
Principal investigator 1 Karyopharm Therapeutics Inc. $1,181.88 01/23/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659705
Principal investigator 1 Karyopharm Therapeutics Inc. $1,363.32 01/23/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659727
Principal investigator 1 Karyopharm Therapeutics Inc. $1,363.32 01/23/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659733
Principal investigator 1 Karyopharm Therapeutics Inc. $1,534.68 01/23/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659747
Principal investigator 1 Karyopharm Therapeutics Inc. $246.96 01/23/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659749
Principal investigator 1 Karyopharm Therapeutics Inc. $1,449.00 01/23/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659751
Principal investigator 1 Karyopharm Therapeutics Inc. $1,363.32 01/23/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659753
Principal investigator 1 Karyopharm Therapeutics Inc. $1,155.42 01/23/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659755
Principal investigator 1 Karyopharm Therapeutics Inc. $1,155.42 01/23/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659759
Principal investigator 1 Karyopharm Therapeutics Inc. $1,363.32 01/23/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659769
Principal investigator 1 Karyopharm Therapeutics Inc. $1,363.32 01/23/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659781
Principal investigator 1 Karyopharm Therapeutics Inc. $1,363.32 01/23/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659783
Principal investigator 1 Karyopharm Therapeutics Inc. $1,449.00 01/23/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659789
Principal investigator 1 Karyopharm Therapeutics Inc. $1,277.64 01/23/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659793
Principal investigator 1 Karyopharm Therapeutics Inc. $1,363.32 01/23/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659801
Principal investigator 1 Karyopharm Therapeutics Inc. $1,363.32 01/23/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659803
Principal investigator 1 Karyopharm Therapeutics Inc. $1,277.64 01/23/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659807
Principal investigator 1 Karyopharm Therapeutics Inc. $246.96 01/23/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659813
Principal investigator 1 Karyopharm Therapeutics Inc. $1,363.32 01/23/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659821
Principal investigator 1 Karyopharm Therapeutics Inc. $1,363.32 01/23/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659829
Principal investigator 1 Karyopharm Therapeutics Inc. $1,277.64 01/23/2025 Covered Recipient Teaching Hospital
Broward Health Medical Center
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma No dispute reported 06/30/2026 1246659831